C hronic heart failure (HF; CHF) is one of the main causes of death in the Western world. Nearly 198 000 hospitalizations for CHF were registered in Italy in 2005, 1 and >8000 patients die of CHF each year in Italy (8159 in 2006) 2 despite substantial implementation of currently recommended medical therapy. January 2013 (CHARM) , 4 the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA), 5 and the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE) 6 studies developed risk scores for patients receiving recommended contemporary pharmacological treatment. However, only the CORONA study, conducted in aged patients with ischemic heart disease and systolic ventricular dysfunction, and the I-PRESERVE, recruiting patients with preserved ejection fraction (EF) of ≥45%, included routine biochemical measurements and collected data on biomarkers.
More recently, MUerte Subita en Insuficiencia Cardiaca (MUSIC) risk score 7 was built on a cohort of 992 consecutive ambulatory CHF patients with a good range of information on biochemical and biomarker measurements. However, this relatively small population was enrolled in a referral setting (heart failure unit of 8 university hospitals), and a few biomarkers included in the prognostic algorithms are not of widely used in CHF. The aim of the present study was to develop a model for predicting mortality in a contemporary cohort of Italian patients recruited in the GISSI-HF trial receiving up-to-date pharmacological therapy, followed for 4 years, with a large amount of information in terms of medical history, biochemical measurements, and hard events. We examined the role of established risk factors and, for a substantial subgroup of patients, the additive role of circulating biomarkers such as natriuretic peptides in predicting mortality.
Methods

Patients
The design and main results of the GISSI-HF trial have been described in detail. 8 A total of 6975 patients with CHF were recruited between August 2002 and February 2005 by a national network involving 326 cardiology and 31 internal medicine departments across Italy (please see the online only Data Supplement Methods section).
Statistical Methods
An extensive list of baseline variables related to prognosis was identified (Table 1) . A Cox proportional hazards model on all-cause death was built using a stepwise procedure with P<0.05 as the inclusion criterion. The variables containing information on concomitant or past medications were excluded from the multivariable analysis because of the impossibility to distinguish causality of treatment effects from selection bias.
For all of the categorical variables, the proportionality of risk required by the Cox model was assessed using Schoenfeld residuals. Quantitative variables were fitted as a single continuous measurement (eg, age, heart rate, body mass index, and hemoglobin), unless there was clear evidence of nonlinearity, as occurred with the estimated glomerular filtration rate (eGFR), left ventricular ejection fraction (LVEF), systolic blood pressure (SBP), uricemia, level of fibrinogen, triglycerides, and QRS duration. Linearity of risk was evaluated by restricted cubic splines 9 for all of the continuous variables, testing whether the nonlinear component was statistically significant. For these latter variables appropriate transformation was applied, modeling them on a continuous scale. Interactions found to be significant in previous studies were examined, such as the interaction of diabetes mellitus with etiology of HF 10, 11 and sex with LVEF. 12 For most variables, <0.8% of the data were missing. However, data were missing in 9.5% of the study population for fibrinogen, 5.9% for bilirubin, and 4.2% for uricemia. A multiple imputation technique based on a Markov chain Monte Carlo approach 13 14 The discriminatory power of the models was assessed by the concordance probability estimate (CPE), 15 a measure similar to the C-statistic but more appropriate in this context because the censoring proportion rises with the C-statistic, whereas the CPE remains stable. Nevertheless, to compare the discriminatory ability of our model with other published models, we have also reported the time-dependent C-statistic. 9 Model calibration was evaluated by assessing predicted and actual outcomes in deciles.
The internal validity of the final predictive models was assessed by the bootstrap resampling technique. 9 For each of 200 bootstrap samples, the model was refitted and tested on the original sample to obtain estimates of predictive accuracy. In a subset of patients with biomarker data available, a multivariable Cox model, including the variables highly associated with the prognosis in the overall population as emerged in the reduced model, was developed to identify risk factors for mortality. The increase in the discriminative value of each biomarker for mortality was assessed by the net reclassification improvement (NRI). 16 This determines the difference in the probability of a patient belonging to predefined risk categories before and after the addition of a specific marker. We evaluated the contribution of high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal probrain natriuretic peptide (NT-proBNP) separately and combined on reclassification compared with a basic model that included clinical risk factors. Patients were initially classified on the basis of estimated risk tertiles. CPE index and C-statistics were calculated for the models. Statistical analyses were done with SAS software, version 9.2 (SAS Institute, Inc., Cary, NC) and with the R program and the rms package (http://CRAN.R-project.org/package=rms).
Results
The study population consisted of 6975 outpatients with CHF. During a median follow-up of 3.9 years, 1969 patients died. The characteristics of survivors and nonsurvivors are shown in Table 1 . Simultaneously considering all of the variables statistically significant in the univariate analysis (P<0.05), the most powerful predictor of death was age, with a linear increase of 4% in hazard for every year ( Table 2) .
The next strongest predictor was eGFR (Figure 1 ), which clearly showed a steady monotonic increase in risk when eGFR is <60. For every unit decrease in eGFR, there was a 1.6% increase in hazard, whereas for eGFR ≥60, no further relationship of increasing eGFR with the risk of death was observed. A similar relationship was also seen for LVEF ( Figure 1 ): for every unit decrease in EF <40%, there was a 2.5% increase in hazard, whereas increasing EF to >40% did not maintain the statistically significant association with death detected in the univariate analysis. One unit increase in SBP caused a 1% decrease in hazard only for SBP <140 mm Hg. The presence of chronic obstructive pulmonary disease (COPD) and a severe New York Heart Association (NYHA) class (III+IV) strongly increased the hazard, by 33% and 28%, respectively. Diabetes mellitus, male sex, aortic stenosis, ischemic etiology, peripheral edema, and >1 previous hospitalization for HF were independent, still highly significant predictors of death. There was a 2% increase in risk per 1-kg/m 2 decrease in body mass index. Among the laboratory measurements, 1 unit increase in uricemia >6.9 mg/dL and decreasing levels of hemoglobin were associated with, respectively, 7% and 5% increases in risk. In decreasing order of importance, hepatomegaly, peripheral vascular disease, QRS duration, atrial fibrillation, decreasing triglycerides, increasing fibrinogen, increasing heart rate, smoking (only ex-smoker versus nonsmokers), third heart sound, and previous pacemaker were further independent predictors of mortality. We found no evidence of any interaction of diabetes mellitus or of sex with the different etiology of HF and with EF for all-cause mortality. The discriminatory ability of the model described, using the imputed data, was moderately strong, with a CPE index for predicting mortality of 0.70 (C-statistic, 0.76). When the model was rerun without imputation, excluding patients with missing variables, the main results were unchanged, with a CPE index similar to the main model at 0.71.
To develop a model that is easier to use in clinical practice, the overall model reported in Table 2 was reduced to include the risk factors that contain the most predictive information ( Table 3 To compare established classification systems with our newly proposed system, we applied the Seattle model to the GISSI-HF database. Although we could not apply exactly the same variables (ie, lymphocytes and statin use were not available), we found a similar performance of the GISSI-HF study (C statistics, 0.737) compared with the Seattle model (C statistics, 0.73). Furthermore, the prognostic contribution of the additional variables emerged in our GISSI-HF model (C statistics, 0.762) on top of the Seattle model, evaluated either in terms of difference in C statistics (P<0.001) or by NRI, was statistically significant (P<0.001), suggesting that our currently proposed model has the advantage compared with the Seattle model in terms of discrimination.
We examined whether the prognostic factors identified in the overall population were still predictive in specific subgroups of clinical interest, such as ischemic etiology versus nonischemic etiology, diabetes mellitus versus nondiabetes mellitus, and COPD versus non-COPD. The strongest factors, such as age, eGFR, EF, SBP, COPD, and NYHA class, were also the strongest predictors of mortality across the subgroups of interest, although some differences emerged for patients with COPD compared with those who were COPD free (Table  S1 , available in the online-only Data Supplement).
Predicting an Individual's Risk
To make it easier to interpret our results, we represented the final reduced model with a nomogram that can be used to calculate a prognostic score and to estimate the risk for death for individual patients (Figure 3) . The predicted probabilities associated with each factor are mapped into points on a scale from 0 to 100. The presence or the level of each predictive factor is associated with a point system allowing us to sum up the points for all of the factors. The total points accumulated by the various covariates correspond with the predicted probability of survival at 2 or 4 years. For example, for a woman with NYHA class III, 70 years old, with body mass index 30, hemoglobin 10, EF 25%, eGFR 40, and COPD, the total score will be given by the sum of 10+67+15+22+10+10+10=144, corresponding with a 2-year survival probability of 0.8. Therefore, this person will have an ≈20% risk of dying at 2 years and a 35% risk of death at 4 years.
Predictors of Mortality in the Population With Biomarkers Levels Available
When we analyzed the subset of 1231 patients with cardiac biomarkers available at baseline (ie, hs-cTnT and NT-proBNP), the multivariable Cox model for mortality (Table 4) showed that NT-proBNP was the strongest predictor (hazard ratio, 1.51 for 1 unit increase on a log scale, P<0.0001) followed by hscTnT (hazard ratio, 1.50 for each unit increase on a log scale, P<0.0001). Severe NYHA class (III+IV), increasing age, and COPD were the next strongest predictors with increases in hazard of, respectively, 51% (P=0.0005), 2% (P=0.0007), and 48% (P=0.002). The introduction of NT-proBNP improved prognostic discrimination for mortality, estimated with NRI, compared with a model that included only clinical risk factors emerged in the reduced model (NRI, 7%; P=0.031), whereas the addition of hs-cTnT to the clinical model (NRI, 5.4%; P=0.061) was borderline significant (Tables S2 and S3 , available in the online-only Data Supplement). The improvement was less marked but still present when the baseline NTproBNP was added to a prognostic model for mortality with clinical risk factors and baseline hs-cTnT (NRI, 4.8%; P=0.08; Table S4 , available in the online-only Data Supplement). 
Discussion
This study, using data from a large clinical trial of CHF patients, confirms the prognostic importance of several baseline characteristics reported in other studies. [3] [4] [5] [6] [7] Our study has identified 25 independent predictors of mortality, the most important 12 factors, age, NYHA class, eGFR, LVEF, COPD, sex, SBP, diabetes mellitus, hemoglobin level, uricemia, aortic stenosis, and body mass index, which contained most of the prognostic information.
This study offers a few important features. First, it is the largest cohort of patients receiving contemporary pharmacological treatment, followed for a long period (median, ≈4 years) and collecting enough fatal events to allow reliable subgroup analyses. Second, routine biochemical measurements were collected for all of the patients, as done only in the CORONA study; this is important given the predictive importance of simple measures, such as eGFR, hemoglobin, uricemia, and fibrinogen, in our models. Third, the patients with HF were enrolled in the GISSI-HF trial according to the all corners principle, regardless of age (>18 years), etiology, and LVEF. Thus, the population is closer to the real world than other HF trials performed thus far. Fourth, the prognostic information provided by each continuous variable, with their ranges of values, means that we could look for specific thresholds of prognostic significance and use each variable discretionally according to its incremental prognostic contribution.
Overall, advancing age, consistently related to worse outcome in several studies, [3] [4] [5] [6] [7] was the strongest risk factor, followed by severe NYHA class. The third most powerful predictor was eGFR, which, as expected, was nonlinearly related to the outcome. Indeed, the relation between worse outcome and lower eGFR was evident only for loss of renal glomerular function (eGFR <60), whereas no trend for risk was observed with higher eGFR (≥60). Another threshold currently used in clinical practice as a strong predictor of mortality was confirmed by assessing the increase in risk for EF <40% in this enrolled population regardless of the EF at baseline. A similar set of variables emerged to be the most predictive in clinical studies on CHF where prognostic scores have been derived previously (Table 5 ).
An important finding in GISSI-HF was the very powerful impact of COPD on mortality associated with 43% increase in risk, consistent with previous investigations on HF. 17, 18 Of note, in our study the diagnosis of COPD was part of the mandatory profile of clinical comorbidities, which had to be prospectively collected by investigators on the basis of established good clinical practice criteria of each center. Aortic stenosis, for which the prevalence is rapidly increasing as the population ages, carries a heavy prognostic burden. Low body mass too is often associated with a poor prognosis in chronic disease, 19, 20 and this was the case for risk of death in GISSI-HF. We also confirmed the prognostic role of decreasing levels of hemoglobin and increasing uricemia (above a threshold of 6.9 mg/dL) as strong predictors of mortality. The prognostic role of triglycerides, which emerged in a previous study, 5 was confirmed. Finally, we examined the prognostic value of 2 important circulating biomarkers measured at baseline in a subset of patients, given their prognostic importance in HF. 5, 6, [21] [22] [23] Their addition to the model weakened the association between clinical risk factors and outcome, confirming their significance on clinical information; however, the other highly significant variables (ie, NYHA, COPD, and age) identified in the overall population maintained their strong predictive value. Interestingly, a single baseline measurement of NT-proBNP or hs-cTnT at baseline provided robust, independent prognostic information in the long run. We have found that, in patients with chronic HF, the risk of mortality rose steeply with increasing levels of biomarker concentrations. hs-cTnT and NT-proBNP are dynamic variables, indicating the state of the heart at the moment of the measurement. Although these 2 markers reflect different pathophysiological mechanisms (myocyte stretch and increased chamber wall tension for NT-proBNP and myocyte injury for hs-cTnT), they are closely correlated (Spearman correlation coefficient=0.57), and their combination did not seem to add substantial prognostic value compared with either marker considered separately.
Although a clinician can stratify risk in a general way based on patient age, NYHA class, clinical characteristics, and laboratory marker findings, it is not possible to integrate the multiple sources of risk information without support from multivariable models. In practice, the goal of simplicity in implementing our findings was achieved by a simple nomogram that can be incorporated in handheld computers.
Study Limitations
Clinical trial databases are selective compared with the patients in observational studies. However, they have the unique advantage of systematic data collection and complete follow-up. In the GISSI-HF study, an all-comers enrollment strategy (no selection for age, etiology, EF, or comorbidities), the large representative network of Italian hospitals and a long follow-up should give a real picture of clinical practice. Biomarkers of known prognostic value in HF that are not yet widely used were tested only in a subset of patients, but were again large enough to permit substantial clinical conclusions. One limitation is represented by the small proportion of patients with preserved LVEF (9.4% with EF>40%) unlike in the CHARM cohort that included a more representative range of left ventricular systolic function (25% of patients with EF >50%). Another limitation is the lack of validation of our predictive model in an external population, although internal validation was good given the strength of our study. However, the prognostic contribution of the additional variables emerged in the GISSI-HF model on the top of the Seattle one was significant. Although the Seattle model seems to be the current frontrunner, we found that our proposed model has the advantage of a higher discriminatory ability compared with the Seattle model, given the wider range of predictors identified.
Finally, GISSI-HF is a 1-country study, and different approaches to HF care across the world may limit the generalizability of our results. However, the center network was fully representative of the national health system. Even if comparisons with other studies are often difficult, our model is closer to CORONA and CHARM than to the Seattle model, and the similarity of many of our findings with CHARM and, above all, with CORONA, despite marked differences in the populations, suggest that they are likely to be valid.
Conclusions
In line with but substantially focusing the findings of previous investigations, we have identified a limited set of demographic, clinical, and biological variables that provide important and independent prognostic information of the risk of death in HF. In a substantial subgroup of patients, the 2 well-known biomarkers (hs-cTnT and NT-proBNP) generally used for diagnostic or short-term prognostication have been specifically suggested as the most powerful predictors of long-term outcome. All of this was used in a multivariable approach leading to a practical nomogram usable at the bedside and, thus, helping clinicians in reliably stratifying the risk of their CHF patients. Outcomes of Exercise TraiNing; NT-proBNP, N-terminal pro-brain natriuretic peptide; ROC, receiver operating characteristic; GISSI-HF, Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Heart Failure; DBP, diastolic blood pressure; BMI, body mass index; NYHA, New York Heart Association; HF, heart failure; CPX, cardiopulmonary exercise; and GFR, glomerular filtration rate.
